Zydus Lifesciences to participate in J.P. Morgan India Conference on September 21
NiveshIQ
NSE: ZYDUSLIFE · Healthcare
Zydus Lifesciences Ltd.
₹1,119.10▲ ₹1.30 (+0.12%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ZYDUSLIFE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Zydus Lifesciences Ltd.
Zydus Lifesciences Limited operates across pharmaceuticals, consumer products, and medical technologies, generating ₹28,592 crore in revenue and ₹4,513 crore in net income in FY24. The pharma segment drives the bulk of sales through generics, specialty formulations, and biosimilars, while the consumer arm contributes with wellness and nutrition brands such as Glucon D and Complan. Recent investments include a ₹128.83 crore stake in Torrent Urja 25 and a share transfer to a promoter group member, signaling strategic expansion and shareholder alignment. The company’s competitive edge lies in its diversified product pipeline, including oncology, autoimmune, and vaccine offerings, and its robust clinical trial capabilities. Despite a 1.29% share price decline on September 4, market sentiment r
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹19,548 Cr +13.40% | ₹23,242 Cr +18.90% | ₹27,148 Cr +16.80% |
| EBITDA Margin | 27.54% | 31.53% | 33.09% |
| Net Profit | ₹3,973 Cr +89.90% | ₹4,834 Cr +21.70% | ₹5,543 Cr +14.70% |
| EPS | ₹38.20 | ₹44.98 | ₹50.09 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Zydus Lifesciences to participate in J.P. Morgan India Conference on September 21
Zydus Lifesciences (NSE:ZYDUSLIFE): What Is Its Role at J.P. Morgan India Conference 2026?
🔒
+ 3 more stories about Zydus Lifesciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹8, 017 Cr, PAT ₹990 Cr, EPS ₹9.35, EBITDA margin 25.4%. Growth context: revenue YoY +20.6%, PAT YoY -99.9%, revenue QoQ +5.7%, PAT QoQ -43.1%. Street verdict: miss, revenue surprise +4.3%, PAT surprise -11.0%.
Management commentary points to order wins, deal pipeline, and backlog build as the primary near-term growth lever, with...
FY26 (last completed FY): revenue ₹27, 148 Cr, PAT ₹5, 543 Cr, EBITDA margin 33.1%, EPS ₹50.09. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ZYDUSLIFE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ZYDUSLIFE alongside your other holdings
Unlock full ZYDUSLIFE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Zydus Lifesciences Ltd.?
NiveshIQ detects active intelligence signals for Zydus Lifesciences Ltd. (ZYDUSLIFE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Zydus Lifesciences Ltd.?
Zydus Lifesciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹11,880,270.4L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.